Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 16/20 | 0.68 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.68 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.67 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.67 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.60 |
| ▸ | PLAU | P00749 | 1/20 | 0.56 |
| ▸ | PLAT | P00750 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.54 |
| ▸ | CHUK | O15111 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MYLK | Q15746 | 1/20 | 0.54 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.54 |
| ▸ | JUN | P05412 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561761 | 0.82 | HTT (0.69) | P2RX1MEN1KMT2AHTT | |
| SCHEMBL16670141 | 0.82 | HTT (0.69) | P2RX1MEN1KMT2AHTT | |
| SCHEMBL28258728 | 0.81 | P2RX1 (1.00) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL14885879 | 0.80 | P2RX1 (1.00) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL4263109 | 0.80 | P2RX1 (0.77) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL3278266 | 0.80 | P2RX1 (1.00) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL127962 | 0.79 | P2RX1 (1.00) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL10797383 | 0.79 | P2RX1 (0.73) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL5060363 | 0.79 | P2RX1 (0.64) | P2RX1P2RX7P2RX4TMPRSS4P2RX3 | |
| SCHEMBL3036995 | 0.79 | P2RX1 (0.58) | P2RX1P2RX7P2RX4TMPRSS4PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060111409-A1 | Medicament for treatment of diabetes | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-25 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060035944-A1 | Remedies for neurodegenerative diseases | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-02-16 | — | — | US | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20060014811-A1 | Medicament for treatment of cancer | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1555018-A1 | REMEDIES FOR NEURODEGENERATIVE DISEASES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | MAP3K1, MAP3K7, MAP3K8 | P2RX1 3942/4885P2RX7 3591/4885P2RX4 4676/4885 |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | P2RX1 4560/4885P2RX7 4213/4885P2RX4 4767/4885 |
| US-20060111409-A1 | Medicament for treatment of diabetes | XDH, SLC5A1, SLC5A2 | P2RX1 3455/4885P2RX7 3383/4885P2RX4 3835/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | P2RX1 2484/4885P2RX7 2360/4885P2RX4 3324/4885 |
| US-20060014811-A1 | Medicament for treatment of cancer | HDAC3, HDAC1, HDAC6 | P2RX1 4850/4885P2RX7 4811/4885P2RX4 4871/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | P2RX1 2927/4885P2RX7 2720/4885P2RX4 3704/4885 |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, TFEB, MAOA | P2RX1 4680/4885P2RX7 4646/4885P2RX4 4774/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | P2RX1 3156/4885P2RX7 3197/4885P2RX4 4233/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | P2RX1 2425/4885P2RX7 2267/4885P2RX4 3298/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | P2RX1 2389/4885P2RX7 2289/4885P2RX4 3242/4885 |
| US-20060035944-A1 | Remedies for neurodegenerative diseases | GLA, CHAT, MAPT | P2RX1 4680/4885P2RX7 4651/4885P2RX4 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.